Ein alternativer Abl-kinase-inhibitor hemmt imatinib-resistenzmutationen des Bcr-Abl-onkogens

Translated title of the contribution: An alternative Abl-kinase inhibitor overcomes imatinib resistance in cells expressing mutant forms of Bcr-Abl

Nikolas Von Bubnoff*, C. Peschel, J. Duyster

*Corresponding author for this work

Fingerprint

Dive into the research topics of 'An alternative Abl-kinase inhibitor overcomes imatinib resistance in cells expressing mutant forms of Bcr-Abl'. Together they form a unique fingerprint.

Biochemistry, Genetics and Molecular Biology

Pharmacology, Toxicology and Pharmaceutical Science